Millennium Management’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $527K | Sell |
311,986
-348,465
| -53% | -$619K | ﹤0.01% | 4742 |
|
|
2025
Q4 | $938K | Buy |
+660,451
| New | +$962K | ﹤0.01% | 4526 |
|
|
2025
Q3 | – | Sell |
-1,382,153
| Closed | -$1.01M | – | 6067 |
|
|
2025
Q2 | $1.01M | Sell |
1,382,153
-1,517,799
| -52% | -$1.31M | ﹤0.01% | 4400 |
|
|
2025
Q1 | $2.34M | Buy |
2,899,952
+1,850,349
| +176% | +$2.13M | ﹤0.01% | 3640 |
|
|
2024
Q4 | $1.45M | Buy |
1,049,603
+252,092
| +32% | +$283K | ﹤0.01% | 3891 |
|
|
2024
Q3 | $829K | Buy |
797,511
+181,483
| +29% | +$249K | ﹤0.01% | 4424 |
|
|
2024
Q2 | $1.07M | Sell |
616,028
-641,335
| -51% | -$1.29M | ﹤0.01% | 4068 |
|
|
2024
Q1 | $3.01M | Sell |
1,257,363
-1,584,956
| -56% | -$3.9M | ﹤0.01% | 3361 |
|
|
2023
Q4 | $9.46M | Buy |
2,842,319
+2,625,640
| +1,212% | +$7.03M | ﹤0.01% | 2245 |
|
|
2023
Q3 | $810K | Sell |
216,679
-635,789
| -75% | -$2.94M | ﹤0.01% | 4331 |
|
|
2023
Q2 | $3.64M | Buy |
852,468
+633,994
| +290% | +$3.74M | ﹤0.01% | 2945 |
|
|
2023
Q1 | $1.49M | Sell |
218,474
-324,147
| -60% | -$2.52M | ﹤0.01% | 3715 |
|
|
2022
Q4 | $4.3M | Buy |
542,621
+25,466
| +5% | +$196K | ﹤0.01% | 2945 |
|
|
2022
Q3 | $4.97M | Buy |
517,155
+127,850
| +33% | +$1.29M | ﹤0.01% | 2894 |
|
|
2022
Q2 | $2.82M | Buy |
389,305
+187,245
| +93% | +$1.63M | ﹤0.01% | 3367 |
|
|
2022
Q1 | $2.61M | Sell |
202,060
-128,381
| -39% | -$1.63M | ﹤0.01% | 3620 |
|
|
2021
Q4 | $5.27M | Sell |
330,441
-153,584
| -32% | -$2.69M | ﹤0.01% | 2856 |
|
|
2021
Q3 | $7.78M | Buy |
484,025
+235,903
| +95% | +$3.46M | ﹤0.01% | 2364 |
|
|
2021
Q2 | $3.43M | Sell |
248,122
-155,288
| -38% | -$2.2M | ﹤0.01% | 3272 |
|
|
2021
Q1 | $5.89M | Buy |
+403,410
| New | +$6.85M | ﹤0.01% | 2393 |
|
|
2020
Q2 | – | Sell |
-353,446
| Closed | -$5.73M | – | 4204 |
|
|
2020
Q1 | $5.73M | Sell |
353,446
-290,997
| -45% | -$5.38M | 0.01% | 1232 |
|
|
2019
Q4 | $11.6M | Buy |
644,443
+570,157
| +768% | +$10.5M | 0.01% | 1262 |
|
|
2019
Q3 | $1.5M | Sell |
74,286
-103,441
| -58% | -$2.07M | ﹤0.01% | 2624 |
|
|
2019
Q2 | $3.93M | Sell |
177,727
-568,635
| -76% | -$9.88M | 0.01% | 1960 |
|
|
2019
Q1 | $10.2M | Buy |
+746,362
| New | +$9.96M | 0.02% | 1231 |
|
|
2018
Q4 | – | Sell |
-516,059
| Closed | -$8.52M | – | 3786 |
|
|
2018
Q3 | $8.52M | Buy |
516,059
+12,454
| +2% | +$221K | 0.01% | 1422 |
|
|
2018
Q2 | $7.05M | Buy |
503,605
+344,240
| +216% | +$4.93M | 0.01% | 1556 |
|
|
2018
Q1 | $1.76M | Sell |
159,365
-535,921
| -77% | -$5.86M | ﹤0.01% | 2392 |
|
|
2017
Q4 | $6.12M | Buy |
695,286
+623,248
| +865% | +$6.67M | 0.01% | 1639 |
|
|
2017
Q3 | $962K | Buy |
72,038
+42,693
| +145% | +$565K | ﹤0.01% | 2537 |
|
|
2017
Q2 | $421K | Sell |
29,345
-666,804
| -96% | -$12.8M | ﹤0.01% | 2886 |
|
|
2017
Q1 | $14.7M | Buy |
696,149
+169,549
| +32% | +$4.17M | 0.03% | 819 |
|
|
2016
Q4 | $14.8M | Sell |
526,600
-480,217
| -48% | -$13.4M | 0.03% | 723 |
|
|
2016
Q3 | $27M | Buy |
1,006,817
+605,877
| +151% | +$16.5M | 0.05% | 454 |
|
|
2016
Q2 | $6.77M | Buy |
+400,940
| New | +$7.53M | 0.02% | 1069 |
|
|
2015
Q4 | – | Sell |
-11,191
| Closed | -$224K | – | 3444 |
|
|
2015
Q3 | $224K | Sell |
11,191
-126,260
| -92% | -$3.84M | ﹤0.01% | 3066 |
|
|
2015
Q2 | $3.97M | Sell |
137,451
-143,548
| -51% | -$3.63M | 0.01% | 1531 |
|
|
2015
Q1 | $8.59M | Buy |
+280,999
| New | +$7.26M | 0.02% | 1106 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Millennium Management's CHRS Position: Q1 2026 in Review
Millennium Management reduced its Coherus Oncology (CHRS) stake by 53% in Q1 2026, selling an estimated $619K and leaving 311,986 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #4742.
Millennium Management first reported a position in CHRS in Q1 2015 and has held it in 38 quarters since. The position peaked at $27M in Q3 2016. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Millennium Management held 311,986 shares of Coherus Oncology worth $527K as of Q1 2026.
- Millennium Management sold 348,465 Coherus Oncology shares in Q1 2026, an estimated $619K.
- Coherus Oncology made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4742 holding.
- Millennium Management first reported a position in Coherus Oncology in Q1 2015 and has held it in 38 quarters since.
- Millennium Management's Coherus Oncology position peaked at $27M in Q3 2016.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.